We appreciate Dr Liner's interest in our paper. We agree, as we stated in the paper, that lincomycin is not a first line drug and should be reserved for the patient population described in his letter.1 Furthermore, we certainly concur that the incidence of pseudomembranous colitis (PMC) following parenteral lincomycin is lese than 2%, in fact much less. If indeed the true incidence is 2%, then the probability of observing one or more cases of PMC in our series of 265 is 0.995, and thus the probability of observing no cases is 0.005.

This content is only available via PDF.
You do not currently have access to this content.